Children's Hospital Boston is a leader in the use of nitric oxide, prostacyclin analogs, endothelin antagonists and other investigational therapies to treat both secondary and primary pulmonary hypertension in children. Innovations such as these are making primary pulmonary hypertension, once presumed irreversible, a treatable and potentially curable disease. Research in this area is ongoing.
Research
Doctors in the Newborn Medicine Department researching pulmonary hypertension:
